Illumina, Inc. (BOVESPA:I1LM34) Stock Price & Quote Analysis

I1LM34 Stock Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

I1LM34 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 62.83% per year

Risk Analysis

Shares are highly illiquid

My Notes

New

Notes are coming soon

Illumina, Inc. Competitors

Mettler-Toledo International

NYSE:MTD

US$34.8b

IQVIA Holdings

NYSE:IQV

US$41.5b

Lonza Group

SWX:LONN

CHF35.9b

Agilent Technologies

NYSE:A

US$46.2b

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share Price	US$206.52
52 Week High	US$396.92
52 Week Low	US$188.10
Beta	1.13
1 Month Change	2.85%
3 Month Change	-10.97%
1 Year Change	-48.59%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-21.91%

Recent updates

Shareholder Returns

	I1LM34	BR Life Sciences	BR Market
7D	0%	0%	0%
1Y	-48.6%	0%	0%

Return vs Industry: I1LM34 underperformed the BR Life Sciences industry which returned -11.5% over the past year.

Return vs Market: I1LM34 underperformed the BR Market which returned -9.2% over the past year.

Price Volatility

Is I1LM34's price volatile compared to industry and market?
I1LM34 volatility
I1LM34 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BR Market	0%
10% least volatile stocks in BR Market	0%

Stable Share Price: Insufficient data to determine I1LM34's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine I1LM34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	9,825	Francis deSouza	https://www.illumina.com

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
I1LM34 fundamental statistics
Market Cap	R$167.43b
Earnings (TTM)	-R$21.63b
Revenue (TTM)	R$24.48b

6.8x

P/S Ratio

-7.7x

P/E Ratio

Is I1LM34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
I1LM34 income statement (TTM)
Revenue	US$4.70b
Cost of Revenue	US$1.42b
Gross Profit	US$3.28b
Other Expenses	US$7.44b
Earnings	-US$4.15b

Last Reported Earnings

Oct 02, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)	-26.40
Gross Margin	69.83%
Net Profit Margin	-88.36%
Debt/Equity Ratio	25.9%

How did I1LM34 perform over the long term?

See historical performance and comparison

I1LM34 Stock Overview

Rewards

Risk Analysis

Illumina, Inc. Competitors

NYSE:MTD

US$34.8b

NYSE:IQV

US$41.5b

SWX:LONN

CHF35.9b

NYSE:A

US$46.2b

Price History & Performance

Recent News & Updates

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Recent updates

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022

Illumina Intends to Appeal EC's Decision in Grail Deal

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

Illumina, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Illumina, Inc.(NasdaqGS:ILMN) dropped from Russell 1000 Growth-Defensive Index

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions

Illumina, Inc. Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina, Inc., Annual General Meeting, May 26, 2022

John Frank Joins Illumina as Chief Public Affairs Officer

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Illumina, Inc. Supports Norway's Pioneering Precision Medicine Study

Randomized Trial Demonstrates Whole-Genome Sequencing Leads to Precision Care for Critically Ill Infants

Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of remaining 85.5% stake in GRAIL, Inc.

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Illumina, Inc. Supports Nationwide Program Across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis

Illumina, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of Fiscal 2021

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Illumina Announces Board Changes

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia

Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

Illumina, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Illumina, Inc. Wins Patent Infringement Suit Against BGI in the UK

Illumina, Inc. Announces the Launch of Illumina Connected Analytics

Kura Oncology, Inc., enters into A Master Collaboration Agreement with Illumina, Inc

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

Emedgene Collaborates with Illumina to Scale the Interpretation of Genomic Data for Rare Diseases

Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

Twist Bioscience Corporation, Illumina, Inc. and Western Digital Corporation Form Alliance with Microsoft to Advance Data Storage in DNA

Illumina, Inc. to Report Q3, 2020 Results on Oct 29, 2020

Illumina, Inc. (NasdaqGS:ILMN) acquired Enancio.

Illumina Reportedly in Talks to Buy Cancer Testing Startup Grail

Illumina, Inc. Announces Withdraw its Fiscal Full Year 2020

Illumina, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Shareholder Returns

Price Volatility

About the Company

Illumina, Inc. Fundamentals Summary

6.8x

-7.7x

Earnings & Revenue